[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]

March 2018 | | ID: T9E17B9AB68EN
FirstWord

US$ 1,095.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This edition presents key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial investigating plasma exchange with Grifols’ human albumin solution, Albutein, combined with intravenous immunoglobulin (IVIG).

Business Questions
  • How successful do KOLs think that p38 MAP kinase alpha inhibition could prove to be as an approach for treating AD?
  • Do the results from the Phase IIa study with neflamapimod confirm its potential activity as a treatment for AD?
  • How important will the REVERSE-SD study be in terms of providing a better understanding of neflamapimod’s role as an AD therapy?
  • Do KOLs think that Elayta’s mechanism of action is compatible with it having a neuroprotective role in patients with AD?
  • Which types of patient are most likely to benefit from treatment with Elayta?
  • How do KOLs perceive plasma exchange as a method for reducing the beta-amyloid load in the brains of patients with AD?
  • Which factors are likely to influence the extent to which plasma exchange with Albutein/IVIG is utilised as a treatment for AD?
  • How do KOLs rate the chances of the AMBAR trial meeting its primary endpoint and plasma exchange therapy with Albutein/IVIG being successfully marketed?


More Publications